Document is current
Any future updates will be listed below
-
Authors
Takahata, Kazuhiko
Tanaka, Eiichi
Sakai, Ryoko
Akazawa, Manabu
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (23K09729)
- License Information
-
More Information
Article History
Received: 19 September 2025
Accepted: 12 December 2025
First Online: 19 December 2025
Declarations
:
: This study was approved by the Meiji Pharmaceutical University Research Ethics Committee in March 2022 (Approval No. 202144). The study adhered to the principles for ethical research outlined in the Declaration of Helsinki.
: Not applicable.
: KT is an employee of Kyowa Kirin Co., Ltd. and has received tuition support for part of his doctoral degree program from the company. ET has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., GlaxoSmithKline K.K., Mikasa Seiyaku co., Ltd., Mitsubishi Tanabe Pharma Co., Nichi-Iko Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc, Sandoz K.K., Taisho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Towa Pharmaceutical Co., Ltd., UCB Japan Co. Ltd. and Viatris Inc. ET received research funding from Pfizer Inc. RS has received consulting fees from Nippon Kayaku Co., Ltd. MA received lectures and consulting fees from Astellas Pharma Inc., Mitsubishi Tanabe Pharma Co., GlaxoSmithKline K.K., and Janssen Pharmaceutical K.K. Peer reviewers for this manuscript have no relevant financial or other relationships to disclose.
